[
  {
    "inputSequence": {
      "header": "unk",
      "SHA512": "d3260284f17ad1200fd8149b47331bce3a5dfd23a872a04b0aef3bbad60913c3fff0f01985105310252041e62861f1581bb25b41ef4ed573063c940c631c5299"
    },
    "subtypeText": "B (2.29%)",
    "validationResults": [],
    "alignedGeneSequences": [
      {
        "firstAA": 1,
        "lastAA": 335,
        "gene": {
          "name": "RT",
          "length": 560
        },
        "mutations": [
          {
            "consensus": "K",
            "position": 49,
            "AAs": "R",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "R",
            "position": 83,
            "AAs": "K",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "K",
            "position": 101,
            "AAs": "E",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "V",
            "position": 106,
            "AAs": "I",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "V",
            "position": 118,
            "AAs": "IV",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "S",
            "position": 162,
            "AAs": "C",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "Y",
            "position": 181,
            "AAs": "C",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "M",
            "position": 184,
            "AAs": "V",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "G",
            "position": 190,
            "AAs": "A",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "T",
            "position": 200,
            "AAs": "I",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "T",
            "position": 215,
            "AAs": "Y",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "K",
            "position": 219,
            "AAs": "E",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "L",
            "position": 228,
            "AAs": "LR",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "V",
            "position": 245,
            "AAs": "L",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "A",
            "position": 272,
            "AAs": "P",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "K",
            "position": 277,
            "AAs": "R",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "E",
            "position": 297,
            "AAs": "K",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "I",
            "position": 329,
            "AAs": "L",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          },
          {
            "consensus": "Q",
            "position": 334,
            "AAs": "E",
            "isInsertion": false,
            "isDeletion": false,
            "isApobecDRM": false
          }
        ],
        "SDRMs": [
          {
            "text": "K101E"
          },
          {
            "text": "Y181C"
          },
          {
            "text": "M184V"
          },
          {
            "text": "G190A"
          },
          {
            "text": "T215Y"
          },
          {
            "text": "K219E"
          }
        ],
        "alignedNAs": "CCCATTAGTCCTATTGAAACTGTACCAGTAAAATTAAARCCAGGAATGGATGGYCCAAAAGTTAAACAATGGCCATTGACAGAAGAAAAAATAAAAGCATTAGTAGAAATTTGTACAGAAATGGAAAAGGAAGGGAAAATTTCAAGAATTGGGCCTGAAAATCCATATAATACTCCAGTATTTGCYATAAAGAAAAAGGACAGTACTAAATGGAGAAAATTAGTAGATTTCAGAGAACTTAATAAGAAAACTCAAGACTTCTGGGAAGTTCAATTAGGAATACCACATCCGGCAGGGTTAGAAAAGAAAAAATCAATAACAGTACTGGATGTAGGTGATGCATATTTTTCARTTCCCTTAGATAAAGACTTCAGGAAGTATACTGCATTTACCATACCTAGTATCAACAATGAGACACCAGGGATTAGATATCAGTACAATGTGCTTCCACAGGGATGGAAAGGATCACCAGCAATATTCCAATGTAGCATGACAAAAATCTTAGAGCCTTTTAGAAAACAAAATCCAGACATAGTTATCTGTCAATACGTGGATGATTTATATGTAGCATCTGACTTAGAAATAGGACAGCATAGAATAAAAATAGAGGAACTGAGACAACATTTGTTGAGGTGGGGATTTTATACACCAGACGAAAAACATCAGAAAGAACCTCCATTCCKTTGGATGGGTTATGAGCTCCATCCTGATAAATGGACAGTACAGCCTATATTGCTGCCAGAAAAAGACAGCTGGACTGTCAATGACATACAGAAGTTAGTGGGAAAATTGAATTGGGCAAGCCAGATTTACCCAGGGATTAAAGTRAGACAATTATGTAAACTMCTTAGGGGAACCAAAGCACTAACAGAAGTAATACCACTAACAAAAGAAGCAGAGCTAGAACTGGCAGAAAACAGGGAAATTCTAAAAGAACCAGTACATGGAGTATATTATGACCCATCAAAAGACTTAATAGCAGAACTACAGAAACAGGGGGAAGGC",
        "alignedAAs": "PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISRIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKKTQDFWEVQLGIPHPAGLEKKKSITVLDVGDAYFSIPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFRKQNPDIVICQYVDDLYVASDLEIGQHRIKIEELRQHLLRWGFYTPDEKHQKEPPFRWMGYELHPDKWTVQPILLPEKDSWTVNDIQKLVGKLNWASQIYPGIKVRQLCKLLRGTKALTEVIPLTKEAELELAENREILKEPVHGVYYDPSKDLIAELQKQGEG",
        "prettyPairwise": {
          "positionLine": [
            " 1 ",
            " 2 ",
            " 3 ",
            " 4 ",
            " 5 ",
            " 6 ",
            " 7 ",
            " 8 ",
            " 9 ",
            "10 ",
            "11 ",
            "12 ",
            "13 ",
            "14 ",
            "15 ",
            "16 ",
            "17 ",
            "18 ",
            "19 ",
            "20 ",
            "21 ",
            "22 ",
            "23 ",
            "24 ",
            "25 ",
            "26 ",
            "27 ",
            "28 ",
            "29 ",
            "30 ",
            "31 ",
            "32 ",
            "33 ",
            "34 ",
            "35 ",
            "36 ",
            "37 ",
            "38 ",
            "39 ",
            "40 ",
            "41 ",
            "42 ",
            "43 ",
            "44 ",
            "45 ",
            "46 ",
            "47 ",
            "48 ",
            "49 ",
            "50 ",
            "51 ",
            "52 ",
            "53 ",
            "54 ",
            "55 ",
            "56 ",
            "57 ",
            "58 ",
            "59 ",
            "60 ",
            "61 ",
            "62 ",
            "63 ",
            "64 ",
            "65 ",
            "66 ",
            "67 ",
            "68 ",
            "69 ",
            "70 ",
            "71 ",
            "72 ",
            "73 ",
            "74 ",
            "75 ",
            "76 ",
            "77 ",
            "78 ",
            "79 ",
            "80 ",
            "81 ",
            "82 ",
            "83 ",
            "84 ",
            "85 ",
            "86 ",
            "87 ",
            "88 ",
            "89 ",
            "90 ",
            "91 ",
            "92 ",
            "93 ",
            "94 ",
            "95 ",
            "96 ",
            "97 ",
            "98 ",
            "99 ",
            "100",
            "101",
            "102",
            "103",
            "104",
            "105",
            "106",
            "107",
            "108",
            "109",
            "110",
            "111",
            "112",
            "113",
            "114",
            "115",
            "116",
            "117",
            "118",
            "119",
            "120",
            "121",
            "122",
            "123",
            "124",
            "125",
            "126",
            "127",
            "128",
            "129",
            "130",
            "131",
            "132",
            "133",
            "134",
            "135",
            "136",
            "137",
            "138",
            "139",
            "140",
            "141",
            "142",
            "143",
            "144",
            "145",
            "146",
            "147",
            "148",
            "149",
            "150",
            "151",
            "152",
            "153",
            "154",
            "155",
            "156",
            "157",
            "158",
            "159",
            "160",
            "161",
            "162",
            "163",
            "164",
            "165",
            "166",
            "167",
            "168",
            "169",
            "170",
            "171",
            "172",
            "173",
            "174",
            "175",
            "176",
            "177",
            "178",
            "179",
            "180",
            "181",
            "182",
            "183",
            "184",
            "185",
            "186",
            "187",
            "188",
            "189",
            "190",
            "191",
            "192",
            "193",
            "194",
            "195",
            "196",
            "197",
            "198",
            "199",
            "200",
            "201",
            "202",
            "203",
            "204",
            "205",
            "206",
            "207",
            "208",
            "209",
            "210",
            "211",
            "212",
            "213",
            "214",
            "215",
            "216",
            "217",
            "218",
            "219",
            "220",
            "221",
            "222",
            "223",
            "224",
            "225",
            "226",
            "227",
            "228",
            "229",
            "230",
            "231",
            "232",
            "233",
            "234",
            "235",
            "236",
            "237",
            "238",
            "239",
            "240",
            "241",
            "242",
            "243",
            "244",
            "245",
            "246",
            "247",
            "248",
            "249",
            "250",
            "251",
            "252",
            "253",
            "254",
            "255",
            "256",
            "257",
            "258",
            "259",
            "260",
            "261",
            "262",
            "263",
            "264",
            "265",
            "266",
            "267",
            "268",
            "269",
            "270",
            "271",
            "272",
            "273",
            "274",
            "275",
            "276",
            "277",
            "278",
            "279",
            "280",
            "281",
            "282",
            "283",
            "284",
            "285",
            "286",
            "287",
            "288",
            "289",
            "290",
            "291",
            "292",
            "293",
            "294",
            "295",
            "296",
            "297",
            "298",
            "299",
            "300",
            "301",
            "302",
            "303",
            "304",
            "305",
            "306",
            "307",
            "308",
            "309",
            "310",
            "311",
            "312",
            "313",
            "314",
            "315",
            "316",
            "317",
            "318",
            "319",
            "320",
            "321",
            "322",
            "323",
            "324",
            "325",
            "326",
            "327",
            "328",
            "329",
            "330",
            "331",
            "332",
            "333",
            "334",
            "335"
          ],
          "refAALine": [
            " P ",
            " I ",
            " S ",
            " P ",
            " I ",
            " E ",
            " T ",
            " V ",
            " P ",
            " V ",
            " K ",
            " L ",
            " K ",
            " P ",
            " G ",
            " M ",
            " D ",
            " G ",
            " P ",
            " K ",
            " V ",
            " K ",
            " Q ",
            " W ",
            " P ",
            " L ",
            " T ",
            " E ",
            " E ",
            " K ",
            " I ",
            " K ",
            " A ",
            " L ",
            " V ",
            " E ",
            " I ",
            " C ",
            " T ",
            " E ",
            " M ",
            " E ",
            " K ",
            " E ",
            " G ",
            " K ",
            " I ",
            " S ",
            " K ",
            " I ",
            " G ",
            " P ",
            " E ",
            " N ",
            " P ",
            " Y ",
            " N ",
            " T ",
            " P ",
            " V ",
            " F ",
            " A ",
            " I ",
            " K ",
            " K ",
            " K ",
            " D ",
            " S ",
            " T ",
            " K ",
            " W ",
            " R ",
            " K ",
            " L ",
            " V ",
            " D ",
            " F ",
            " R ",
            " E ",
            " L ",
            " N ",
            " K ",
            " R ",
            " T ",
            " Q ",
            " D ",
            " F ",
            " W ",
            " E ",
            " V ",
            " Q ",
            " L ",
            " G ",
            " I ",
            " P ",
            " H ",
            " P ",
            " A ",
            " G ",
            " L ",
            " K ",
            " K ",
            " K ",
            " K ",
            " S ",
            " V ",
            " T ",
            " V ",
            " L ",
            " D ",
            " V ",
            " G ",
            " D ",
            " A ",
            " Y ",
            " F ",
            " S ",
            " V ",
            " P ",
            " L ",
            " D ",
            " K ",
            " D ",
            " F ",
            " R ",
            " K ",
            " Y ",
            " T ",
            " A ",
            " F ",
            " T ",
            " I ",
            " P ",
            " S ",
            " I ",
            " N ",
            " N ",
            " E ",
            " T ",
            " P ",
            " G ",
            " I ",
            " R ",
            " Y ",
            " Q ",
            " Y ",
            " N ",
            " V ",
            " L ",
            " P ",
            " Q ",
            " G ",
            " W ",
            " K ",
            " G ",
            " S ",
            " P ",
            " A ",
            " I ",
            " F ",
            " Q ",
            " S ",
            " S ",
            " M ",
            " T ",
            " K ",
            " I ",
            " L ",
            " E ",
            " P ",
            " F ",
            " R ",
            " K ",
            " Q ",
            " N ",
            " P ",
            " D ",
            " I ",
            " V ",
            " I ",
            " Y ",
            " Q ",
            " Y ",
            " M ",
            " D ",
            " D ",
            " L ",
            " Y ",
            " V ",
            " G ",
            " S ",
            " D ",
            " L ",
            " E ",
            " I ",
            " G ",
            " Q ",
            " H ",
            " R ",
            " T ",
            " K ",
            " I ",
            " E ",
            " E ",
            " L ",
            " R ",
            " Q ",
            " H ",
            " L ",
            " L ",
            " R ",
            " W ",
            " G ",
            " F ",
            " T ",
            " T ",
            " P ",
            " D ",
            " K ",
            " K ",
            " H ",
            " Q ",
            " K ",
            " E ",
            " P ",
            " P ",
            " F ",
            " L ",
            " W ",
            " M ",
            " G ",
            " Y ",
            " E ",
            " L ",
            " H ",
            " P ",
            " D ",
            " K ",
            " W ",
            " T ",
            " V ",
            " Q ",
            " P ",
            " I ",
            " V ",
            " L ",
            " P ",
            " E ",
            " K ",
            " D ",
            " S ",
            " W ",
            " T ",
            " V ",
            " N ",
            " D ",
            " I ",
            " Q ",
            " K ",
            " L ",
            " V ",
            " G ",
            " K ",
            " L ",
            " N ",
            " W ",
            " A ",
            " S ",
            " Q ",
            " I ",
            " Y ",
            " A ",
            " G ",
            " I ",
            " K ",
            " V ",
            " K ",
            " Q ",
            " L ",
            " C ",
            " K ",
            " L ",
            " L ",
            " R ",
            " G ",
            " T ",
            " K ",
            " A ",
            " L ",
            " T ",
            " E ",
            " V ",
            " I ",
            " P ",
            " L ",
            " T ",
            " E ",
            " E ",
            " A ",
            " E ",
            " L ",
            " E ",
            " L ",
            " A ",
            " E ",
            " N ",
            " R ",
            " E ",
            " I ",
            " L ",
            " K ",
            " E ",
            " P ",
            " V ",
            " H ",
            " G ",
            " V ",
            " Y ",
            " Y ",
            " D ",
            " P ",
            " S ",
            " K ",
            " D ",
            " L ",
            " I ",
            " A ",
            " E ",
            " I ",
            " Q ",
            " K ",
            " Q ",
            " G ",
            " Q ",
            " G "
          ],
          "alignedNAsLine": [
            "CCC",
            "ATT",
            "AGT",
            "CCT",
            "ATT",
            "GAA",
            "ACT",
            "GTA",
            "CCA",
            "GTA",
            "AAA",
            "TTA",
            "AAR",
            "CCA",
            "GGA",
            "ATG",
            "GAT",
            "GGY",
            "CCA",
            "AAA",
            "GTT",
            "AAA",
            "CAA",
            "TGG",
            "CCA",
            "TTG",
            "ACA",
            "GAA",
            "GAA",
            "AAA",
            "ATA",
            "AAA",
            "GCA",
            "TTA",
            "GTA",
            "GAA",
            "ATT",
            "TGT",
            "ACA",
            "GAA",
            "ATG",
            "GAA",
            "AAG",
            "GAA",
            "GGG",
            "AAA",
            "ATT",
            "TCA",
            "AGA",
            "ATT",
            "GGG",
            "CCT",
            "GAA",
            "AAT",
            "CCA",
            "TAT",
            "AAT",
            "ACT",
            "CCA",
            "GTA",
            "TTT",
            "GCY",
            "ATA",
            "AAG",
            "AAA",
            "AAG",
            "GAC",
            "AGT",
            "ACT",
            "AAA",
            "TGG",
            "AGA",
            "AAA",
            "TTA",
            "GTA",
            "GAT",
            "TTC",
            "AGA",
            "GAA",
            "CTT",
            "AAT",
            "AAG",
            "AAA",
            "ACT",
            "CAA",
            "GAC",
            "TTC",
            "TGG",
            "GAA",
            "GTT",
            "CAA",
            "TTA",
            "GGA",
            "ATA",
            "CCA",
            "CAT",
            "CCG",
            "GCA",
            "GGG",
            "TTA",
            "GAA",
            "AAG",
            "AAA",
            "AAA",
            "TCA",
            "ATA",
            "ACA",
            "GTA",
            "CTG",
            "GAT",
            "GTA",
            "GGT",
            "GAT",
            "GCA",
            "TAT",
            "TTT",
            "TCA",
            "RTT",
            "CCC",
            "TTA",
            "GAT",
            "AAA",
            "GAC",
            "TTC",
            "AGG",
            "AAG",
            "TAT",
            "ACT",
            "GCA",
            "TTT",
            "ACC",
            "ATA",
            "CCT",
            "AGT",
            "ATC",
            "AAC",
            "AAT",
            "GAG",
            "ACA",
            "CCA",
            "GGG",
            "ATT",
            "AGA",
            "TAT",
            "CAG",
            "TAC",
            "AAT",
            "GTG",
            "CTT",
            "CCA",
            "CAG",
            "GGA",
            "TGG",
            "AAA",
            "GGA",
            "TCA",
            "CCA",
            "GCA",
            "ATA",
            "TTC",
            "CAA",
            "TGT",
            "AGC",
            "ATG",
            "ACA",
            "AAA",
            "ATC",
            "TTA",
            "GAG",
            "CCT",
            "TTT",
            "AGA",
            "AAA",
            "CAA",
            "AAT",
            "CCA",
            "GAC",
            "ATA",
            "GTT",
            "ATC",
            "TGT",
            "CAA",
            "TAC",
            "GTG",
            "GAT",
            "GAT",
            "TTA",
            "TAT",
            "GTA",
            "GCA",
            "TCT",
            "GAC",
            "TTA",
            "GAA",
            "ATA",
            "GGA",
            "CAG",
            "CAT",
            "AGA",
            "ATA",
            "AAA",
            "ATA",
            "GAG",
            "GAA",
            "CTG",
            "AGA",
            "CAA",
            "CAT",
            "TTG",
            "TTG",
            "AGG",
            "TGG",
            "GGA",
            "TTT",
            "TAT",
            "ACA",
            "CCA",
            "GAC",
            "GAA",
            "AAA",
            "CAT",
            "CAG",
            "AAA",
            "GAA",
            "CCT",
            "CCA",
            "TTC",
            "CKT",
            "TGG",
            "ATG",
            "GGT",
            "TAT",
            "GAG",
            "CTC",
            "CAT",
            "CCT",
            "GAT",
            "AAA",
            "TGG",
            "ACA",
            "GTA",
            "CAG",
            "CCT",
            "ATA",
            "TTG",
            "CTG",
            "CCA",
            "GAA",
            "AAA",
            "GAC",
            "AGC",
            "TGG",
            "ACT",
            "GTC",
            "AAT",
            "GAC",
            "ATA",
            "CAG",
            "AAG",
            "TTA",
            "GTG",
            "GGA",
            "AAA",
            "TTG",
            "AAT",
            "TGG",
            "GCA",
            "AGC",
            "CAG",
            "ATT",
            "TAC",
            "CCA",
            "GGG",
            "ATT",
            "AAA",
            "GTR",
            "AGA",
            "CAA",
            "TTA",
            "TGT",
            "AAA",
            "CTM",
            "CTT",
            "AGG",
            "GGA",
            "ACC",
            "AAA",
            "GCA",
            "CTA",
            "ACA",
            "GAA",
            "GTA",
            "ATA",
            "CCA",
            "CTA",
            "ACA",
            "AAA",
            "GAA",
            "GCA",
            "GAG",
            "CTA",
            "GAA",
            "CTG",
            "GCA",
            "GAA",
            "AAC",
            "AGG",
            "GAA",
            "ATT",
            "CTA",
            "AAA",
            "GAA",
            "CCA",
            "GTA",
            "CAT",
            "GGA",
            "GTA",
            "TAT",
            "TAT",
            "GAC",
            "CCA",
            "TCA",
            "AAA",
            "GAC",
            "TTA",
            "ATA",
            "GCA",
            "GAA",
            "CTA",
            "CAG",
            "AAA",
            "CAG",
            "GGG",
            "GAA",
            "GGC"
          ],
          "mutationLine": [
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " R ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " K ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " E ",
            " - ",
            " - ",
            " - ",
            " - ",
            " I ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            "VI ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " C ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " C ",
            " - ",
            " - ",
            " V ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " A ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " I ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " Y ",
            " - ",
            " - ",
            " - ",
            " E ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            "LR ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " L ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " P ",
            " - ",
            " - ",
            " - ",
            " - ",
            " R ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " K ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " - ",
            " L ",
            " - ",
            " - ",
            " - ",
            " - ",
            " E ",
            " - "
          ]
        }
      }
    ],
    "drugResistance": [
      {
        "version": {
          "text": "8.8",
          "publishDate": "2019-02-13"
        },
        "gene": {
          "name": "RT"
        },
        "drugScores": [
          {
            "drugClass": {
              "name": "NRTI"
            },
            "drug": {
              "name": "ABC",
              "displayAbbr": "ABC"
            },
            "score": 30.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "M184V",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
                      }
                    ]
                  }
                ],
                "score": 15.0
              },
              {
                "mutations": [
                  {
                    "text": "T215Y",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
                      }
                    ]
                  }
                ],
                "score": 10.0
              },
              {
                "mutations": [
                  {
                    "text": "K219E",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
                      }
                    ]
                  }
                ],
                "score": 5.0
              }
            ],
            "text": "Intermediate Resistance"
          },
          {
            "drugClass": {
              "name": "NRTI"
            },
            "drug": {
              "name": "AZT",
              "displayAbbr": "AZT"
            },
            "score": 40.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "M184V",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
                      }
                    ]
                  }
                ],
                "score": -10.0
              },
              {
                "mutations": [
                  {
                    "text": "T215Y",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
                      }
                    ]
                  }
                ],
                "score": 40.0
              },
              {
                "mutations": [
                  {
                    "text": "K219E",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
                      }
                    ]
                  }
                ],
                "score": 10.0
              }
            ],
            "text": "Intermediate Resistance"
          },
          {
            "drugClass": {
              "name": "NRTI"
            },
            "drug": {
              "name": "D4T",
              "displayAbbr": "D4T"
            },
            "score": 40.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "M184V",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
                      }
                    ]
                  }
                ],
                "score": -10.0
              },
              {
                "mutations": [
                  {
                    "text": "T215Y",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
                      }
                    ]
                  }
                ],
                "score": 40.0
              },
              {
                "mutations": [
                  {
                    "text": "K219E",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
                      }
                    ]
                  }
                ],
                "score": 10.0
              }
            ],
            "text": "Intermediate Resistance"
          },
          {
            "drugClass": {
              "name": "NRTI"
            },
            "drug": {
              "name": "DDI",
              "displayAbbr": "DDI"
            },
            "score": 30.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "M184V",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
                      }
                    ]
                  }
                ],
                "score": 10.0
              },
              {
                "mutations": [
                  {
                    "text": "T215Y",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
                      }
                    ]
                  }
                ],
                "score": 15.0
              },
              {
                "mutations": [
                  {
                    "text": "K219E",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
                      }
                    ]
                  }
                ],
                "score": 5.0
              }
            ],
            "text": "Intermediate Resistance"
          },
          {
            "drugClass": {
              "name": "NRTI"
            },
            "drug": {
              "name": "FTC",
              "displayAbbr": "FTC"
            },
            "score": 60.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "M184V",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
                      }
                    ]
                  }
                ],
                "score": 60.0
              }
            ],
            "text": "High-Level Resistance"
          },
          {
            "drugClass": {
              "name": "NRTI"
            },
            "drug": {
              "name": "LMV",
              "displayAbbr": "3TC"
            },
            "score": 60.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "M184V",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
                      }
                    ]
                  }
                ],
                "score": 60.0
              }
            ],
            "text": "High-Level Resistance"
          },
          {
            "drugClass": {
              "name": "NRTI"
            },
            "drug": {
              "name": "TDF",
              "displayAbbr": "TDF"
            },
            "score": 5.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "M184V",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
                      }
                    ]
                  }
                ],
                "score": -10.0
              },
              {
                "mutations": [
                  {
                    "text": "T215Y",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
                      }
                    ]
                  }
                ],
                "score": 10.0
              },
              {
                "mutations": [
                  {
                    "text": "K219E",
                    "primaryType": "NRTI",
                    "comments": [
                      {
                        "type": "NRTI",
                        "text": "K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
                      }
                    ]
                  }
                ],
                "score": 5.0
              }
            ],
            "text": "Susceptible"
          },
          {
            "drugClass": {
              "name": "NNRTI"
            },
            "drug": {
              "name": "DOR",
              "displayAbbr": "DOR"
            },
            "score": 65.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "K101E",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 15.0
              },
              {
                "mutations": [
                  {
                    "text": "V106I",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. "
                      }
                    ]
                  }
                ],
                "score": 15.0
              },
              {
                "mutations": [
                  {
                    "text": "Y181C",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 10.0
              },
              {
                "mutations": [
                  {
                    "text": "K101E",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
                      }
                    ]
                  },
                  {
                    "text": "G190A",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 5.0
              },
              {
                "mutations": [
                  {
                    "text": "Y181C",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
                      }
                    ]
                  },
                  {
                    "text": "G190A",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 20.0
              }
            ],
            "text": "High-Level Resistance"
          },
          {
            "drugClass": {
              "name": "NNRTI"
            },
            "drug": {
              "name": "EFV",
              "displayAbbr": "EFV"
            },
            "score": 95.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "K101E",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 15.0
              },
              {
                "mutations": [
                  {
                    "text": "Y181C",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 30.0
              },
              {
                "mutations": [
                  {
                    "text": "G190A",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 45.0
              },
              {
                "mutations": [
                  {
                    "text": "K101E",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
                      }
                    ]
                  },
                  {
                    "text": "Y181C",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 5.0
              }
            ],
            "text": "High-Level Resistance"
          },
          {
            "drugClass": {
              "name": "NNRTI"
            },
            "drug": {
              "name": "ETR",
              "displayAbbr": "ETR"
            },
            "score": 85.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "K101E",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 15.0
              },
              {
                "mutations": [
                  {
                    "text": "V106I",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. "
                      }
                    ]
                  }
                ],
                "score": 10.0
              },
              {
                "mutations": [
                  {
                    "text": "Y181C",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 30.0
              },
              {
                "mutations": [
                  {
                    "text": "G190A",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 10.0
              },
              {
                "mutations": [
                  {
                    "text": "K101E",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
                      }
                    ]
                  },
                  {
                    "text": "Y181C",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 5.0
              },
              {
                "mutations": [
                  {
                    "text": "K101E",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
                      }
                    ]
                  },
                  {
                    "text": "G190A",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 5.0
              },
              {
                "mutations": [
                  {
                    "text": "Y181C",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
                      }
                    ]
                  },
                  {
                    "text": "G190A",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 10.0
              }
            ],
            "text": "High-Level Resistance"
          },
          {
            "drugClass": {
              "name": "NNRTI"
            },
            "drug": {
              "name": "NVP",
              "displayAbbr": "NVP"
            },
            "score": 165.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "K101E",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 30.0
              },
              {
                "mutations": [
                  {
                    "text": "V106I",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. "
                      }
                    ]
                  }
                ],
                "score": 10.0
              },
              {
                "mutations": [
                  {
                    "text": "Y181C",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 60.0
              },
              {
                "mutations": [
                  {
                    "text": "G190A",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 60.0
              },
              {
                "mutations": [
                  {
                    "text": "K101E",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
                      }
                    ]
                  },
                  {
                    "text": "Y181C",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 5.0
              }
            ],
            "text": "High-Level Resistance"
          },
          {
            "drugClass": {
              "name": "NNRTI"
            },
            "drug": {
              "name": "RPV",
              "displayAbbr": "RPV"
            },
            "score": 125.0,
            "partialScores": [
              {
                "mutations": [
                  {
                    "text": "K101E",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 45.0
              },
              {
                "mutations": [
                  {
                    "text": "V106I",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "V106I is occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It likely plays a greater role in reducing DOR susceptibility, particularly in combination with other NNRTI-associated DRMs. "
                      }
                    ]
                  }
                ],
                "score": 10.0
              },
              {
                "mutations": [
                  {
                    "text": "Y181C",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 45.0
              },
              {
                "mutations": [
                  {
                    "text": "G190A",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 15.0
              },
              {
                "mutations": [
                  {
                    "text": "Y181C",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
                      }
                    ]
                  },
                  {
                    "text": "G190A",
                    "primaryType": "NNRTI",
                    "comments": [
                      {
                        "type": "NNRTI",
                        "text": "G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
                      }
                    ]
                  }
                ],
                "score": 10.0
              }
            ],
            "text": "High-Level Resistance"
          }
        ]
      }
    ]
  }
]